<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Genet</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Genet</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Genet.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Genetics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1664-8021</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7013921</article-id>
    <article-id pub-id-type="doi">10.3389/fgene.2020.00029</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Genetics</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>CHG: A Systematically Integrated Database of Cancer Hallmark Genes</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Denan</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn003">
          <sup>†</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Huo</surname>
          <given-names>Diwei</given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn003">
          <sup>†</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xie</surname>
          <given-names>Hongbo</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn003">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/741330"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wu</surname>
          <given-names>Lingxiang</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn003">
          <sup>†</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Juan</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/763529"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Lei</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Jin</surname>
          <given-names>Qing</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Xiujie</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn001">
          <sup>*</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/762792"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>College of Bioinformatics Science and Technology, Harbin Medical University</institution>, <addr-line>Harbin</addr-line>, <country>China</country></aff>
    <aff id="aff2"><sup>2</sup><institution>The 2nd Affiliated Hospital of Harbin Medical University</institution>, <addr-line>Harbin</addr-line>, <country>China</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p>Edited by: Lei Deng, Central South University, China</p>
      </fn>
      <fn fn-type="edited-by">
        <p>Reviewed by: Jiajie Peng, Northwestern Polytechnical University, China; Xuekun Ren, Harbin Institute of Technology, China; Qiang Lei, Harbin Institute of Technology, China</p>
      </fn>
      <corresp id="fn001">*Correspondence: Xiujie Chen, <email xlink:href="mailto:chenxiujie@ems.hrbmu.edu.cn" xlink:type="simple">chenxiujie@ems.hrbmu.edu.cn</email>
</corresp>
      <fn fn-type="other" id="fn002">
        <p>This article was submitted to Statistical Genetics and Methodology, a section of the journal Frontiers in Genetics</p>
      </fn>
      <fn fn-type="equal" id="fn003">
        <p>†These authors have contributed equally to this work and share first authorship</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>05</day>
      <month>2</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2020</year>
    </pub-date>
    <volume>11</volume>
    <elocation-id>29</elocation-id>
    <history>
      <date date-type="received">
        <day>01</day>
        <month>7</month>
        <year>2019</year>
      </date>
      <date date-type="accepted">
        <day>09</day>
        <month>1</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2020 Zhang, Huo, Xie, Wu, Zhang, Liu, Jin and Chen</copyright-statement>
      <copyright-year>2020</copyright-year>
      <copyright-holder>Zhang, Huo, Xie, Wu, Zhang, Liu, Jin and Chen</copyright-holder>
      <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <sec>
        <title>Background</title>
        <p>The analysis of cancer diversity based on a logical framework of hallmarks has greatly improved our understanding of the occurrence, development and metastasis of various cancers.</p>
      </sec>
      <sec>
        <title>Methods</title>
        <p>We designed Cancer Hallmark Genes (CHG) database which focuses on integrating hallmark genes in a systematic, standard way and annotates the potential roles of the hallmark genes in cancer processes. Following the conceptual criteria description of hallmark function the keywords for each hallmark were manually selected from the literature. Candidate hallmark genes collected were derived from 301 pathways of KEGG database by Lucene and manually corrected.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p>Based on the variation data, we finally identified the hallmark genes of various types of cancer and constructed CHG. And we also analyzed the relationships among hallmarks and potential characteristics and relationships of hallmark genes based on the topological structures of their networks. We manually confirm the hallmark gene identified by CHG based on literature and database. We also predicted the prognosis of breast cancer, glioblastoma multiforme and kidney papillary cell carcinoma patients based on CHG data.</p>
      </sec>
      <sec>
        <title>Conclusions</title>
        <p>In summary, CHG, which was constructed based on a hallmark feature set, provides a new perspective for analyzing the diversity and development of cancers.</p>
      </sec>
    </abstract>
    <kwd-group>
      <kwd>Hallmark genes</kwd>
      <kwd>mutation</kwd>
      <kwd>methylation</kwd>
      <kwd>copy number variation</kwd>
      <kwd>annotating Hallmark features</kwd>
      <kwd>database</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content></funding-source>
      </award-group>
    </funding-group>
    <counts>
      <fig-count count="8"/>
      <table-count count="3"/>
      <equation-count count="0"/>
      <ref-count count="45"/>
      <page-count count="10"/>
      <word-count count="5019"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <title>Introduction</title>
    <p>In 2000, <xref rid="B13" ref-type="bibr">Weinberg et al. (2000)</xref> first proposed six hallmarks of cancer, including Sustaining Proliferative Signaling (SPS), Evading Growth Suppressors (EGS), Resisting Cell Death (RCD), Enabling Replicative Immortality (ERI), Inducing Angiogenesis (IA), and Activating Invasion and Metastasis (AIM), which provided a logical framework for conceptualizing a variety of neoplastic diseases. In 2011, they added another four hallmarks to more fully capture the features of cancers, including Genome Instability and Mutation (GIM), Tumor-Promoting Inflammation (TPI), Reprogramming Energy Metabolism (REM), and Evading Immune Destruction (EID) (<xref rid="B14" ref-type="bibr">Hanahan and Weinberg, 2011</xref>). The hallmarks of cancer capture the most essential phenotypic characteristics of malignant transformation and progression, but numerous factors involved in this multistep process are still unknown to date. It is undoubtedly that the framework constructed by hallmarks has greatly improved the analysis on diversity of cancers. Balázs Győrffy et al. reviewed the available techniques that are capable of and appropriate for determining the characteristic features of each hallmark (<xref rid="B26" ref-type="bibr">Menyhart et al., 2016</xref>). Hallmark capabilities are regulated by partially redundant signaling pathways, and the significance of these pathways depends on the tumor's underlying molecular features. Recently, many studies have focused on the integration of various cancer-related pathways or genes for analysis, and they have found some significant results. In 2011, Jie Li et al. identified high-quality breast cancer prognostic markers and metastasis network modules by integrating hallmark-related genes from GO terms (<xref rid="B24" ref-type="bibr">Li et al., 2010</xref>). In 2013, Naif Zaman et al. predicted breast cancer subtype-specific drug targets by exploring the modules (including apoptosis, cell proliferation and cell cycle) in a signaling network assessment of mutations and copy number variations (CNVs) (<xref rid="B43" ref-type="bibr">Zaman et al., 2013</xref>). These researches strongly emphasized the importance of constructing gene sets for hallmarks. Moreover, the advantages of the analysis based on a hallmark framework are notable: 1) It reduces feature dimension of cancer (more attention will be focused on the significant genes in each hallmark rather than on all genes, which will reduce the large number of passenger genes analyzed). 2) It is explicable (the results of analysis are depicted more easily). 3) It provides a potential avenue for exploring the mechanism of carcinogenesis. However, the overlap rate of the hallmark genes in current studies is low because the studies use different extraction methods. Furthermore, no gene sets have been systematically collected for the different hallmarks thus far, which makes it difficult to clarify the gene alteration features (including mutations, DNA methylations and CNVs) in each hallmark (<xref rid="B39" ref-type="bibr">Wang et al., 2015</xref>).</p>
    <p>To address this problem, we established a database called Cancer Hallmark Genes in (CHG), which provides gene sets for the ten hallmarks and the corresponding statistical analysis results, including the frequency of different mutation types (e.g., missense, deletion, insertion), methylation and CNV (e.g., loss or gain) for each gene. To maximize the usage of our database, we collected a total of 22697 samples from TCGA and analyzed the variations of mutation, CNV, and methylation of hallmark genes across 34 cancer types.</p>
    <p>Furthermore, we analyzed the relationship among ten hallmarks by Fisher's exact test and unsupervised hierarchical clustering (method 2). Eventually, the hallmarks were clustered into four classes: 1) Reprogramming Energy Metabolism (REM). 2) Activating Invasion and Metastasis (AIM), Evading Growth Suppressors (EGS), Enabling Replicative Immortality (ERI), and Sustaining Proliferative Signaling (SPS). 3) Genome Instability and Mutation (GIM). 4) Tumor-Promoting Inflammation (TPI), Evading Immune Destruction (EID), Resisting Cell Death (RCD), and Inducing Angiogenesis (IA).</p>
    <p>Even though the hallmark genes identified in the database came from the confirmed literature and databases, we manually confirmed the top 10 altered (mutation, methylation, CNV) genes of each hallmark to further ensure the accuracy of the data. In addition, we also used several of cancers as examples for further analysis with the CHG data to demonstrate the value of this database at a practical level.</p>
    <p>The CHG database is freely available at our website: <uri xlink:type="simple" xlink:href="http://www.bio-bigdata.com/CHG/index.html">http://www.bio-bigdata.com/CHG/index.html</uri>.</p>
  </sec>
  <sec sec-type="materials|methods" id="s2">
    <title>Materials and Methods</title>
    <sec id="s2_1">
      <title>Data for Hallmarks</title>
      <p>In this work, 301 pathways were downloaded from KEGG (version 78.0) (<xref rid="B19" ref-type="bibr">Kanehisa et al., 2017</xref>). This data was used for Lucene search and extraction of pathway genes. Gene variant data (7,075 samples of mutation in 34 cancers, 6,177 samples of methylation in 20 cancers, 9445 samples of CNV in 33 cancers) from TCGA (<xref rid="B34" ref-type="bibr">Stratton et al., 2013</xref>) were downloaded, where the methylated data was selected as JHU_USC (HumanMethylation 450) and BI (Genome_Wide_SNP_6) was selected for CNV data. These data were used to calculate the frequency of gene variation, and the proportion of different types of variation. The data in this article across DNA methylation, mutation and CNV were from the same samples of TCGA database. In the TCGA database, there are strict rules for the sequencing, processing and analysis, etc. of the samples data and provide standardized data downloading. Human protein-protein interaction data was downloaded from HPRD (<xref rid="B20" ref-type="bibr">Keshava Prasad et al., 2009</xref>), STRING (<xref rid="B36" ref-type="bibr">Szklarczyk et al., 2011</xref>), BioGRID (<xref rid="B3" ref-type="bibr">Chatraryamontri et al., 2013</xref>) and HTRIdb (<xref rid="B2" ref-type="bibr">Bovolenta et al., 2012</xref>). Human gene regulation data was downloaded from HTRIdb. These data were used to integrate an integrated gene interaction network. The cDNA data (GRCh38 version and GRCh37 version) was downloaded from Ensembl (<xref rid="B9" ref-type="bibr">Flicek et al., 2014</xref>). This data was used for the processing of CNV data (<xref ref-type="supplementary-material" rid="ST3"><bold>Supplementary Table 3</bold></xref>).</p>
    </sec>
    <sec id="s2_2">
      <title>The Construction Process of the CHG Database</title>
      <p>Following the conceptual criteria description of hallmark function in the article “Hallmarks of Cancer: The Next Generation,” published in Cell in 2011, we searched the relevant literature in PubMed, and screened the high-frequency descriptive vocabulary appearing in the abstract of the literature as the key words of the corresponding Hallmark. The core idea of our CHG database is to transform the conceptual description of Hallmark features into real biological processes and their corresponding entities. So, we built a process that consists of three main steps (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>).</p>
      <fig id="f1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>CHG construction flow chart. The CHG database uses a process consisting of three main steps to transform a conceptual description of Hallmark features into real biological processes and their corresponding entities.</p>
        </caption>
        <graphic xlink:href="fgene-11-00029-g001"/>
      </fig>
      <p>First, we identify the Hallmark description keyword. This step is to materialize the conceptual description of the Hallmark feature. The relevant literature is determined by searching the Hallmark feature description in the literature, and the specific descriptors associated with each Hallmark feature are determined by identifying the high frequency vocabulary in the relevant document abstract. In this step, we manually confirmed the results from the literature scan. In addition to determining that the identified keywords are related to the Hallmark feature, some of the words without more information such as “cancer” and “tumor” are not directly provided to vocabulary. At the same time, we also further enrich the identified Hallmark description keywords through synonym expansion, for example, “apoptosis” and “cell death” (<xref ref-type="supplementary-material" rid="ST1"><bold>Supplementary Table 1</bold></xref>).</p>
      <p>Second, we use a text mining software package Lucene to identify the Hallmark-specific pathways in the literature and KEGG database based on the Hallmark description keywords identified in the previous step. The result of the identification is manually confirmed again. The manual confirmation step does not add any subjective results, and only in the case of certainty, significant unrelated results due to software recognition errors are removed (<xref ref-type="supplementary-material" rid="ST1"><bold>Supplementary Tables 1</bold></xref> , <xref ref-type="supplementary-material" rid="ST2"><bold>2</bold></xref>).</p>
      <p>Finally, genes with potential specificity in the potential Hallmark-specific pathway were screened from gene mutation level, epigenetic level, and CNV level to construct CHG.</p>
    </sec>
    <sec id="s2_3">
      <title>Cancer Type-Specific Variant Gene</title>
      <p>Based on the variation data in TCGA (<xref rid="B27" ref-type="bibr">Montenegro et al., 2015</xref>), we calculated the variations of mutation, methylation and CNV for these hallmark genes in different types of cancers. Mutation, CNV, and methylation signatures were used as part of the filtration function in the Hallmark-specific gene screening process in our construction of the CHG database. This is because the relationship between these features and cancer has been confirmed in extensive and in-depth discussions in many previous studies (<xref rid="B17" ref-type="bibr">Kan et al., 2010</xref>; <xref rid="B18" ref-type="bibr">Kandoth et al., 2013</xref>; <xref rid="B21" ref-type="bibr">Laddha et al., 2014</xref>; <xref rid="B42" ref-type="bibr">Wu et al., 2017</xref>; <xref rid="B1" ref-type="bibr">Bouras et al., 2019</xref>; <xref rid="B33" ref-type="bibr">Sina et al., 2019</xref>; <xref rid="B38" ref-type="bibr">Tate et al., 2019</xref>). The variations in the characteristics of these different types of cancer not only provide more detailed information for analysis based on the hallmarks but also can be used as a “fingerprint” of cancer type or progression, and this cancer classification can be used as further guidance in prognosis and clinical treatment (<xref ref-type="supplementary-material" rid="ST3"><bold>Supplementary Table 3</bold></xref>).</p>
      <sec id="s2_3_1">
        <title>Gene Mutation</title>
        <p>Based on the somatic mutation (level 2) data for the 34 types of cancers in TCGA, the frequency of each mutated gene was calculated in specific cancers(<xref rid="B6" ref-type="bibr">Chung et al., 2016</xref>). To account for the specific action of different somatic mutations in different types or periods of cancers, we mainly studied the following six types of somatic mutations: insertion (INS), deletion (DEL), missense mutations (SNP_mis), nonsense mutations (SNP_non), splice site mutations (SNP_spl), and gene silencing (SNP_sil) (<xref rid="B16" ref-type="bibr">Hu et al., 2018</xref>). The proportion of mutation types in each type of cancer was also statistically analyzed (<xref rid="B17" ref-type="bibr">Kan et al., 2010</xref>; <xref rid="B18" ref-type="bibr">Kandoth et al., 2013</xref>).</p>
      </sec>
      <sec id="s2_3_2">
        <title>DNA Methylation</title>
        <p>We carried out the following calculations for the level 3 data from 20 human tumors derived from TCGA that simultaneously contained both cancer and control samples (<xref rid="B1" ref-type="bibr">Bouras et al., 2019</xref>; <xref rid="B33" ref-type="bibr">Sina et al., 2019</xref>):</p>
        <list list-type="alpha-lower">
          <list-item>
            <p>Calculate the methylation beta value of each sample (including cancer and normal samples). For genes with multiple methylation sites, the average beta value represents the gene methylation values. The average beta value of the gene in all normal samples was calculated as the methylation level of the control group (<xref rid="B38" ref-type="bibr">Tate et al., 2019</xref>);</p>
          </list-item>
          <list-item>
            <p>When the gene methylation absolute beta value between the cancer and control groups was more than 0.5, it was called a methylation altered gene. We calculated the occurrence frequency of methylation variation and the corresponding beta value of each gene (<xref rid="B38" ref-type="bibr">Tate et al., 2019</xref>).</p>
          </list-item>
          <list-item>
            <p>If the gene's methylated beta value was greater than 0.8 in the cancer samples, it was labeled as H (high), whereas when the methylated beta value was less than 0.2, it was labeled as L (low). We calculated the proportion of genes belonging to H or L (<xref rid="B38" ref-type="bibr">Tate et al., 2019</xref>).</p>
          </list-item>
        </list>
      </sec>
      <sec id="s2_3_3">
        <title>Copy Number Variation</title>
        <p>We analyzed gene segments for the CNV based on level 3 data derived from TCGA and cDNA data from Ensembl in 33 human tumors that simultaneously contained both cancer and control samples. For each pair of samples, if the CNV occurred in only one sample, the default value of the segment in any other sample was 0. Based on experience, we chose 0.2 and -0.2 as the thresholds for altered CNV genes; we marked the gene as a “gain” when the segment value was greater than 0.2 in the cancer samples and as a “loss” when the segment value was less than -0.2 (<xref rid="B21" ref-type="bibr">Laddha et al., 2014</xref>). We counted the frequency of CNV in the genes and the proportion of genes belonging to the “gain” and “loss” categories.</p>
      </sec>
    </sec>
    <sec id="s2_4">
      <title>Analysis of Relationships of Hallmarks</title>
      <p>We analyzed the relationships among the ten hallmarks by Fisher's exact test and unsupervised hierarchical clustering (<xref rid="B37" ref-type="bibr">Tan et al., 2011</xref>; <xref rid="B15" ref-type="bibr">Hashemi et al., 2013</xref>). We compared the relationship between the specific gene sets of two hallmarks to the final recognition of the overall relationships among the 10 hallmarks. We separately calculated the number of genes belonging to two hallmarks, only one hallmark and all hallmarks. Based on the null hypothesis of independence between any two hallmarks, we calculated the similarity through Fisher's exact test. Finally, we carried out hierarchical clustering with the 1-P value as the similarity score.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s3">
    <title>Results</title>
    <sec id="s3_1">
      <title>The Features of Hallmark Genes Across Cancers</title>
      <p>Genome variation is a common phenomenon in cancer, and it is essential to understanding the internal mechanism and prognosis of the tumor in terms of whether the hallmark-related genes have a generally or specifically altered pattern. To this end, we processed the somatic mutation data, methylation data and copy number variant data for 34 cancers in TCGA and analyzed the frequency of somatic mutations, methylation and CNVs in different cancer types (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>).</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Numbers of pathways and genes of 10 hallmarks.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="center" rowspan="1" colspan="1">Hallmarks of cancer</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Num. of pathway</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Num. of genes</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">AIM</td>
              <td valign="top" align="center" rowspan="1" colspan="1">9</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1,101</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">ERI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">4</td>
              <td valign="top" align="center" rowspan="1" colspan="1">302</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">EGS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">4</td>
              <td valign="top" align="center" rowspan="1" colspan="1">678</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">RCD</td>
              <td valign="top" align="center" rowspan="1" colspan="1">24</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1,150</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">SPS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">27</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1,263</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">EID</td>
              <td valign="top" align="center" rowspan="1" colspan="1">15</td>
              <td valign="top" align="center" rowspan="1" colspan="1">591</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">TPI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">12</td>
              <td valign="top" align="center" rowspan="1" colspan="1">619</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GIM</td>
              <td valign="top" align="center" rowspan="1" colspan="1">10</td>
              <td valign="top" align="center" rowspan="1" colspan="1">221</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">IA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3</td>
              <td valign="top" align="center" rowspan="1" colspan="1">483</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">REM</td>
              <td valign="top" align="center" rowspan="1" colspan="1">9</td>
              <td valign="top" align="center" rowspan="1" colspan="1">440</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>To promote the analysis of carcinogenesis, we mapped the driven mutation, methylation and CNV gene data from TCGA into hallmarks to analyze the altered percentages of all hallmark genes. We found that, among all hallmark genes, 97.39% of the genes were altered by mutation, 33.44% were regulated by methylation, and 84.88% were influenced by CNV (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref>). In each hallmark, the ratio of genes altered by mutation, methylation and CNV was more than 95% (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>). These results indicate that the genomic changes in cancer are widespread.</p>
      <fig id="f2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Distribution of genomic changes in 10 hallmarks. The frequency of mutation is about 97.39%, the frequency of methylation is about 33.44% and the frequency of CNV is about 84.88%.</p>
        </caption>
        <graphic xlink:href="fgene-11-00029-g002"/>
      </fig>
      <table-wrap id="T2" position="float">
        <label>Table 2</label>
        <caption>
          <p>Ratio of altered Genes in hallmarks.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="center" rowspan="1" colspan="1">Hallmarks</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Num. of driven Mutation genes</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Num. of driven Methylation genes</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Num. of driven CNV genes</th>
              <th valign="top" align="center" rowspan="1" colspan="1">alteration genes/all driven genes</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Ratio of altered Genes</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">AIM</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1,098</td>
              <td valign="top" align="center" rowspan="1" colspan="1">334</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1,003</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1,098/1,101</td>
              <td valign="top" align="center" rowspan="1" colspan="1">99.73%</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">ERI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">301</td>
              <td valign="top" align="center" rowspan="1" colspan="1">88</td>
              <td valign="top" align="center" rowspan="1" colspan="1">277</td>
              <td valign="top" align="center" rowspan="1" colspan="1">301/302</td>
              <td valign="top" align="center" rowspan="1" colspan="1">99.67%</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">EGS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">617</td>
              <td valign="top" align="center" rowspan="1" colspan="1">234</td>
              <td valign="top" align="center" rowspan="1" colspan="1">491</td>
              <td valign="top" align="center" rowspan="1" colspan="1">645/678</td>
              <td valign="top" align="center" rowspan="1" colspan="1">95.13%</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">RCD</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1147</td>
              <td valign="top" align="center" rowspan="1" colspan="1">349</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1,025</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1,147/1,150</td>
              <td valign="top" align="center" rowspan="1" colspan="1">99.74%</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">SPS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1261</td>
              <td valign="top" align="center" rowspan="1" colspan="1">356</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1,160</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1,261/1,263</td>
              <td valign="top" align="center" rowspan="1" colspan="1">99.84%</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">EID</td>
              <td valign="top" align="center" rowspan="1" colspan="1">583</td>
              <td valign="top" align="center" rowspan="1" colspan="1">258</td>
              <td valign="top" align="center" rowspan="1" colspan="1">506</td>
              <td valign="top" align="center" rowspan="1" colspan="1">583/591</td>
              <td valign="top" align="center" rowspan="1" colspan="1">98.65%</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">TPI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">614</td>
              <td valign="top" align="center" rowspan="1" colspan="1">230</td>
              <td valign="top" align="center" rowspan="1" colspan="1">537</td>
              <td valign="top" align="center" rowspan="1" colspan="1">614/619</td>
              <td valign="top" align="center" rowspan="1" colspan="1">99.19%</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GIM</td>
              <td valign="top" align="center" rowspan="1" colspan="1">220</td>
              <td valign="top" align="center" rowspan="1" colspan="1">73</td>
              <td valign="top" align="center" rowspan="1" colspan="1">187</td>
              <td valign="top" align="center" rowspan="1" colspan="1">220/221</td>
              <td valign="top" align="center" rowspan="1" colspan="1">99.55%</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">IA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">482</td>
              <td valign="top" align="center" rowspan="1" colspan="1">198</td>
              <td valign="top" align="center" rowspan="1" colspan="1">427</td>
              <td valign="top" align="center" rowspan="1" colspan="1">482/483</td>
              <td valign="top" align="center" rowspan="1" colspan="1">99.79%</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">REM</td>
              <td valign="top" align="center" rowspan="1" colspan="1">438</td>
              <td valign="top" align="center" rowspan="1" colspan="1">95</td>
              <td valign="top" align="center" rowspan="1" colspan="1">402</td>
              <td valign="top" align="center" rowspan="1" colspan="1">438/440</td>
              <td valign="top" align="center" rowspan="1" colspan="1">99.55%</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>For each hallmark, the ratio of genes altered by mutation, methylation, and CNV were more than 95%.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>We counted the number of hallmark genes that are mutated, differentially methylated and copied in 34 different cancer types (<xref ref-type="fig" rid="f3"><bold>Figure 3</bold></xref>). The results showed that the difference among the number of mutated genes in different cancer types is large, and there is a 9-fold difference between the maximum and the minimum number of mutated genes, with 2644 in LIHC (liver hepatocellular carcinoma) and 281 in LAML (acute myeloid leukemia). The largest number of differentially methylated genes is 490 in BRCA (breast invasive carcinoma), and the smallest number is 34 in LUAD (lung adenocarcinoma). The largest number of differentially CNV genes is 1972 in OV (ovarian serous cystadenocarcinoma), and the smallest number is 267 in THYM (thymoma).</p>
      <fig id="f3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Number of variant genes of Hallmarks in different cancer types. The number of hallmark genes with mutated, differentially methylated and copied in 34 different cancer types. It is showed that different types of cancer have different alteration characteristics.</p>
        </caption>
        <graphic xlink:href="fgene-11-00029-g003"/>
      </fig>
      <p>We also found that different types of cancer have different alteration characteristics. As shown in <xref ref-type="fig" rid="f3"><bold>Figure 3</bold></xref>, some cancers, such as SKCM (skin cutaneous melanoma), ESCA (esophageal carcinoma), LIHC (liver hepatocellular carcinoma), mainly reflect the mutation pattern of the genome, and this is a common pattern in most cancers. Some cancers, such as PCPG (pheochromocytoma and paraganglioma), LAML (acute myeloid leukemia), and OV (ovarian serous cystadenocarcinoma), mainly reflect a pattern of CNV variation, which suggests that we should analyze the specific alteration patterns in specific cancers when uncovering the functional importance of the genomic alterations and the underlying mechanisms that drive cancer development, progression and metastasis in different cancer types.</p>
    </sec>
    <sec id="s3_2">
      <title>Network of Hallmark Genes</title>
      <p>The potential characteristics and relationships of hallmark genes can be effectively revealed based on the topological structures of their networks. Since the hallmark genes were identified from qualitative analysis without any relevant interaction information, we mapped these hallmark genes onto the integrated protein regulatory network to collect data on the interaction and regulation relationships between the hallmark genes and the extract interactions between the hallmark genes, which resulted in the construction of 10 hallmark subnetworks. The average degree of the integrated protein interactions is 36 and 54 in the regulation network and the entire hallmark network (constructed by all the hallmark interaction genes), respectively. This indicates that the interaction between hallmarks is higher than the average level of integrated protein interactions and shows that hallmark networks are more closely linked. On average, for the 10 hallmark subnetworks, 94% of the hallmark genes were involved in the network (<xref ref-type="supplementary-material" rid="SF1"><bold>Supplementary Figure 1</bold></xref>). We performed an analysis of the 10 subnetworks and calculated the degree, betweenness and clustering coefficient of all nodes. We found that, in addition to the GIM network in <xref ref-type="fig" rid="f4"><bold>Figure 4</bold></xref>, the gene interactions inside each hallmark subnetwork were more closely related than the interactions between the 10 hallmark subnetworks. This result may be due to GIM as the basis of other hallmarks; genetic diversity of GIM will lead to in other hallmark features (<xref rid="B14" ref-type="bibr">Hanahan and Weinberg, 2011</xref>). At the same time, we also analyzed the correlation between the degree and number of genes in each subnetwork. The results showed that genes with large degrees often also have larger betweenness, as there was a positive correlation between these variables (<xref ref-type="supplementary-material" rid="SF1"><bold>Supplementary Figure 1</bold></xref>).</p>
      <fig id="f4" position="float">
        <label>Figure 4</label>
        <caption>
          <p>The average degree of ten hallmarks. In addition to the GIM network, the gene interactions inside each hallmark subnetwork were more closely related than the interactions between the 10 hallmark subnetworks.</p>
        </caption>
        <graphic xlink:href="fgene-11-00029-g004"/>
      </fig>
    </sec>
    <sec id="s3_3">
      <title>Relationship of Hallmarks</title>
      <p>Ten types of hallmarks described different aspects of the tumor characteristics, but there were few relationships mentioned between these characteristics on a pan-cancer scale. To this end, we analyzed the relationship among the hallmarks and divided the ten hallmarks into four classes (<xref ref-type="fig" rid="f5"><bold>Figure 5</bold></xref>). Interestingly, we found two classes with only one hallmark, namely, <italic>Reprogramming Energy Metabolism (REM)</italic> and <italic>Genome Instability and Mutation (GIM)</italic>. This result is reasonable, as both of these hallmarks are clearly different from the other hallmarks in terms of their mechanisms. As we know, almost all types of cancers are caused by DNA mutation or genome structure alterations and are followed by the appearance of other hallmarks.</p>
      <fig id="f5" position="float">
        <label>Figure 5</label>
        <caption>
          <p>Relationship among ten hallmarks. The relationship among the hallmarks on a pan-cancer scale. There are two classes with only one hallmark, Reprogramming Energy Metabolism (REM) and Genome Instability and Mutation (GIM) and both of these hallmarks are clearly different from the other hallmarks in terms of their mechanisms. In addition, the similarity among the hallmarks Activating Invasion and Metastasis (AIM), Evading Growth Suppressors (EGS), Enabling Replicative Immortality (ERI), and Sustaining Proliferative Signaling (SPS) is prominent. Many of the hallmarks in this set are related to the preliminary stage of cancers. The last class includes Tumor-Promoting Inflammation (TPI), Evading Immune Destruction (EID), Resisting Cell Death (RCD), and Inducing Angiogenesis (IA). Noticeably, tumor-promoting inflammation may activate the response of immune system, and many recent studies have focused on the relationship between inflammation and the immune system in cancers.</p>
        </caption>
        <graphic xlink:href="fgene-11-00029-g005"/>
      </fig>
      <p>In addition, the similarity among the hallmarks Activating Invasion and Metastasis (AIM), Evading Growth Suppressors (EGS), Enabling Replicative Immortality (ERI) and Sustaining Proliferative Signaling (SPS) is prominent. Many of the hallmarks in this set are related to the preliminary stage of cancers (<xref rid="B13" ref-type="bibr">Hanahan and Weinberg, 2000</xref>; <xref rid="B14" ref-type="bibr">Hanahan and Weinberg, 2011</xref>). One confusing inclusion in the set is AIM, which is a hallmark that is considered to be related to the end stage of cancers. However, recent research has also found that AIM occurs in early cancers as well (<xref rid="B14" ref-type="bibr">Hanahan and Weinberg, 2011</xref>).</p>
      <p>The last class includes <italic>Tumor-Promoting Inflammation (TPI), Evading Immune Destruction (EID), Resisting Cell Death (RCD)</italic>, and <italic>Inducing Angiogenesis (IA)</italic>. Noticeably, tumor-promoting inflammation may activate the response of immune system, and many recent studies have focused on the relationship between inflammation and the immune system in cancers (<xref rid="B12" ref-type="bibr">Grivennikov et al., 2010</xref>; <xref rid="B37" ref-type="bibr">Tan et al., 2011</xref>; <xref rid="B8" ref-type="bibr">Elinav et al., 2013</xref>; <xref rid="B15" ref-type="bibr">Hashemi et al., 2013</xref>).</p>
      <p>In addition, we further analyzed the patterns of characteristic variation of the hallmark genes (<xref ref-type="fig" rid="f6"><bold>Figure 6</bold></xref>) in 34 different cancers (<xref ref-type="supplementary-material" rid="ST3"><bold>Supplementary Table 3</bold></xref>). We looked at the top 10 altered features (e.g., mutation, CNV or methylation) of each hallmark gene as the Typical Characteristics of the Hallmark Gene (TCHG, <xref ref-type="supplementary-material" rid="ST4"><bold>Supplementary Table 4</bold></xref>). In heat map analysis, we can clearly find major differences between the TCHGs as altered patterns in different types of cancer. In fact, these features can be used as simple markers for distinguishing cancer types.</p>
      <fig id="f6" position="float">
        <label>Figure 6</label>
        <caption>
          <p>The pattern of characteristic variation of Hallmark genes in 34 different cancers. Heat map shows major differences between the altered features (e.g., mutation, CNV or methylation) of each hallmark gene as altered patterns in different types of cancer. In fact, these features can be used as simple markers for distinguishing cancer types.</p>
        </caption>
        <graphic xlink:href="fgene-11-00029-g006"/>
      </fig>
    </sec>
    <sec id="s3_4">
      <title>Validation of CHG Data</title>
      <p>Although the hallmark-related genes identified in the database came from the confirmed literature and databases, we manually confirmed the TCHG to further ensure the accuracy of the data. Considering the very large dataset that we had to confirm, we have currently verified only the top 10 altered (mutation, methylation, CNV) genes of each hallmark. Over 92% of the typical characteristic genes have explanations of their specific hallmark functions in the literature, which demonstrates the accuracy and precision of the CHG data on a theoretical level (<xref ref-type="supplementary-material" rid="ST4"><bold>Supplementary Table 4</bold></xref>).</p>
      <p>In addition, we compared the results of this study with existing Sanger Cancer Gene Census databases (<xref rid="B11" ref-type="bibr">Futreal et al., 2004</xref>). The Sanger Cancer Gene Census database not only describes the genomic features of cancer-related genes themselves, but also includes information on tissue distribution, mutation information and protein structure. We also compared 699 cancer-related genes identified in the Sanger Cancer Gene Census database with the Typical Characteristics of the Hallmark Gene (TCHG) we identified. Of the 139 Hallmark-related TCHG genes we identified, 69 were also included in the Sanger database, accounting for 49.7%. These results also confirm the accuracy of our results. For other genes that are not included in the Sanger database, we also confirm their important role in cancer-related biological processes through literature verification, such as ETS1 (<xref rid="B40" ref-type="bibr">Watabe et al., 1998</xref>; <xref rid="B10" ref-type="bibr">Fujimoto et al., 2004</xref>; <xref rid="B45" ref-type="bibr">Zhang et al., 2014</xref>; <xref rid="B25" ref-type="bibr">Li et al., 2015</xref>) and RHOA (<xref rid="B23" ref-type="bibr">Lee et al., 2015</xref>; <xref rid="B44" ref-type="bibr">Zeng et al., 2015</xref>; <xref rid="B35" ref-type="bibr">Sun et al., 2016</xref>) in hallmark “Activating Invasion and Metastasis”.</p>
    </sec>
    <sec id="s3_5">
      <title>CHG Case Study</title>
      <p>In addition, we used breast cancer data that was labeled as recurrent or not recurrent as samples for further analysis based on the CHG data. These analyses can be used as an example of the applications of the CHG database and can also prove the value of this database at a practical level. We performed a significant enrichment analysis of the differentially expressed genes based on data from 159 breast cancer patients from GEO with a significance level of p &lt; 0.01. The sample group and the control group were patient data with and without recurrence, respectively. In particular, these differentially expressed genes were filtered by hallmark genes from the CHG database before performing the enrichment analysis. We found that these genes were enriched in 2 out of the 10 hallmarks, corresponding to the hallmarks whose main functions include <italic>Genome Instability and Mutation (GIM)</italic> and <italic>Tumor-Promoting Inflammation (TPI)</italic> (<xref rid="T3" ref-type="table"><bold>Table 3</bold></xref>). It is well known that tumor development is jointly promoted by cell-intrinsic and cell-extrinsic factors. The hallmarks in <xref rid="T3" ref-type="table"><bold>Table 3</bold></xref> include risk factors for tumor recurrence that are both extracellular (<italic>Tumor-Promoting Inflammation</italic>) and intracellular (<italic>Genome Instability and Mutation</italic>). These results not only expressed the theoretical interpretation of the enrichment analysis but also reflected the significance of the hallmark genes in the CHG database.</p>
      <table-wrap id="T3" position="float">
        <label>Table 3</label>
        <caption>
          <p>Hallmark function of differentially expressed genes based on 137 breast cancer data.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">Hallmark</th>
              <th valign="top" align="left" rowspan="1" colspan="1">P-value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Genome Instability and Mutation</td>
              <td valign="top" align="left" rowspan="1" colspan="1">0.000121</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Tumor-Promoting Inflammation</td>
              <td valign="top" align="left" rowspan="1" colspan="1">0.004591</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The accuracy and specificity of the hallmark genes identified in CHG can also be confirmed by our analysis of the survival data for cancer patients. The survival analysis based on TCGA data was carried out with only hallmark genes as a single block, and it showed that patient groups with differentially expressed (compared to the average expression level) hallmark markers could clearly distinguish the prognosis of patients with high statistical significance. Similar results have been found in many types of cancer. For instance, in a survival analysis of 1183 breast cancer patients and 156 glioblastoma multiforme patients, only the expression level of hallmark genes could clearly distinguish the length of the survival time in the prognosis (<xref ref-type="fig" rid="f7"><bold>Figure 7</bold></xref>). In addition, the hallmark gene identified by CHG can also be used as a marker to determine the recurrence of cancer to some extent. An analysis of the survival data of 284 KIRP (kidney papillary cell carcinoma) patients with 27 recurrence cases in <xref ref-type="fig" rid="f8"><bold>Figure 8</bold></xref> shows that the hallmark genes identified in CHG have good sensitivity for distinguishing cancer recurrence. These results fully showed that the variation characteristics of the hallmark-related genes in CHG were representative, and they could be directly applied to rapid qualitative analysis.</p>
      <fig id="f7" position="float">
        <label>Figure 7</label>
        <caption>
          <p>Hallmark genes could clearly distinguish the length of the survival time in the prognosis. In a survival analysis of 1,183 breast cancer patients (up) and 156 glioblastoma multiforme patients (down), only the expression level of hallmark genes could clearly distinguish the length of the survival time in the prognosis.</p>
        </caption>
        <graphic xlink:href="fgene-11-00029-g007"/>
      </fig>
      <fig id="f8" position="float">
        <label>Figure 8</label>
        <caption>
          <p>CHG hallmark genes can be used as a marker to determine the recurrence of cancer. An analysis of the survival data of 284 KIRP (kidney papillary cell carcinoma) patients with 27 recurrence cases shows that the hallmark genes identified in CHG have good sensitivity for distinguishing cancer recurrence.</p>
        </caption>
        <graphic xlink:href="fgene-11-00029-g008"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s4">
    <title>Discussion</title>
    <p>Since Weinberg et al. firstly established the hallmarks for cancer in 2000, many studies have focused on the analysis of cancer based on a framework constructed by these hallmarks. In addition, in 2011, the number of hallmarks increased to ten, which indicates that the features of cancer may be exceedingly complex. Perhaps unsurprisingly, in 2013, another hallmark, <italic>Aberrant Alternative Splicing</italic>, was proposed by Michael Ladomery (<xref rid="B22" ref-type="bibr">Ladomery, 2013</xref>). It has been reported that the vast majority of human genes, possibly over 94%, are alternatively spliced (<xref rid="B28" ref-type="bibr">Pan et al., 2008</xref>). In 2015, MF Montenegro et al. targeted the epigenetic machinery of cancer cells and noted that there was increasing evidence linking the aberrant regulation of methylation to carcinogenesis (<xref rid="B27" ref-type="bibr">Montenegro et al., 2015</xref>), which implied that it may be a potential hallmark for cancer. In 2015, Mamatha Bhat et al. published a review about the translation machinery in cancer. They mentioned that translation played a major role in the regulation of gene expression, and the dysregulation of this process is considered a hallmark of cancer.</p>
    <p>The CHG database that we constructed is based on the ten hallmarks that Weinberg proposed in 2011. As a specifically designed framework constructed from a hallmark database, CHG can provide a new perspective for an analysis of the diversity and development of cancers as well as a convenient method for in-depth data mining. The CHG database focused on integrating hallmark genes, annotating the potential roles of hallmark features in human cancer processes, and evaluating the relationships of the ten hallmarks by constructing hallmark networks and calculating the degree and distance between genes belonging to each network. Even though the hallmark-related genes identified in the database have been confirmed by consensus from the literature and databases, we manually confirmed the top 10 altered (mutation, methylation, CNV) genes in each hallmark to further ensure the accuracy of our data.</p>
    <p>According to our plan, CHG database will be updated regularly every year to supplement the new findings in hallmark field or revise the existing results. We will also follow up the study of cancer hallmarks, the update of important data source (such as revision of TCGA or KEGG) and improve the practicality of CHG database in mechanism interpretation and clinical aspects. All of old version database would also be maintained and access to downloaded. The difference of each version of database would be listed.</p>
    <p>Furthermore, over the past decade, analysis based on the integration of multiple datasets has become quite prevalent. In 2013, Du et al. (<xref rid="B7" ref-type="bibr">Du et al., 2013</xref>) analyzed clinically relevant long noncoding RNAs in human cancer by integrating SCNA (somatic copy number alteration), lncRNA and clinical data. In 2014, <xref rid="B41" ref-type="bibr">Wu et al., (2014)</xref> predicted disease-causing nonsynonymous single nucleotide variants by integrating multiple genomic datasets. <xref rid="B32" ref-type="bibr">Sanchez et al., (2014)</xref> integrated an analysis of Chip-Seq and RNA-Seq data to unveil an lncRNA tumor suppressor signature. Many studies, such as the work of Peng et al., have determined that miRNAs are a widely regulated regulatory mechanism in cancer (<xref rid="B30" ref-type="bibr">Peng et al., 2019b</xref>). Hence, it is worthwhile to integrate non-coding RNA (including miRNA, lncRNA, etc.) (<xref rid="B4" ref-type="bibr">Cheng et al., 2016</xref>; <xref rid="B5" ref-type="bibr">Cheng et al., 2019</xref>), fusion genes and drug information into a database. We have set out to construct a network that is comprised of these non-coding RNAs, genes and drugs. We hope that the next step will be to provide an online analysis tool (such as <xref rid="B29" ref-type="bibr">Peng et al., 2019a</xref>; <xref rid="B31" ref-type="bibr">Peng et al., 2019c</xref>) to provide further personalized analysis. We will gather these resources into the database in the next version, and we anticipate that the database will help promote the analysis of cancer and the identification of valuable drug targets.</p>
  </sec>
  <sec sec-type="data-availability" id="s5">
    <title>Data Availability Statement</title>
    <p>The CHG database is freely available at our website: <uri xlink:type="simple" xlink:href="http://www.bio-bigdata.com/CHG/index.html">http://www.bio-bigdata.com/CHG/index.html</uri>.</p>
  </sec>
  <sec id="s6">
    <title>Author Contributions</title>
    <p>DZ, DH, HX, and LW contributed equally to this work and should be considered co-first authors. JZ, LL, and HX collected data and conducts calculation and analysis. DH, QJ, and XC analyzed the results. DZ and LW wrote the paper. All authors reviewed the manuscript.</p>
  </sec>
  <sec sec-type="funding-information" id="s7">
    <title>Funding</title>
    <p>This work was supported by the National Natural Science Foundation of China [Grant No. 61671191, 61971166, 61701142, 61802090].</p>
  </sec>
  <sec id="s8">
    <title>Conflict of Interest</title>
    <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
</body>
<back>
  <ack>
    <title>Acknowledgments</title>
    <p>We are very grateful to Professor Xiujie Chen and Professor Hongbo Zhou for their suggestions and comments to this research.</p>
  </ack>
  <sec id="s9" sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fgene.2020.00029/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fgene.2020.00029/full#supplementary-material</ext-link></p>
    <supplementary-material content-type="local-data" id="SF1">
      <label>Supplementary Figure 1</label>
      <caption>
        <p>Topological characteristics of hallmark gene networks.</p>
      </caption>
      <media xlink:href="Image_1.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="ST1">
      <label>Supplementary Table 1</label>
      <caption>
        <p>Characteristic pathways of different hallmarker with mapping keys.</p>
      </caption>
      <media xlink:href="Table_1.xls">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="ST2">
      <label>Supplementary Table 2</label>
      <caption>
        <p>Genesets of 10 hallmarker.</p>
      </caption>
      <media xlink:href="Table_2.xls">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="ST3">
      <label>Supplementary Table 3</label>
      <caption>
        <p>Specific genes in 34 cancer type of mutation.</p>
      </caption>
      <media xlink:href="Table_3.xls">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="ST4">
      <label>Supplementary Table 4</label>
      <caption>
        <p>Literature validation of TOP10 altered (mutation, methylation, CNV) genes (TCHGs) of each hallmark.</p>
      </caption>
      <media xlink:href="Table_4.xls">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouras</surname><given-names>E.</given-names></name><name><surname>Karakioulaki</surname><given-names>M.</given-names></name><name><surname>Bougioukas</surname><given-names>K. I.</given-names></name><name><surname>Aivaliotis</surname><given-names>M.</given-names></name><name><surname>Tzimagiorgis</surname><given-names>G.</given-names></name><name><surname>Chourdakis</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Gene promoter methylation and cancer: An umbrella review</article-title>. <source>Gene</source>
<volume>710</volume>, <fpage>333</fpage>–<lpage>340</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2019.06.023</pub-id>
<pub-id pub-id-type="pmid">31202904</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bovolenta</surname><given-names>L. A.</given-names></name><name><surname>Acencio</surname><given-names>M. L.</given-names></name><name><surname>Lemke</surname><given-names>N.</given-names></name></person-group> (<year>2012</year>). <article-title>HTRIdb: an open-access database for experimentally verified human transcriptional regulation interactions</article-title>. <source>BMC Genomics</source>
<volume>13</volume>, <fpage>405</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2164-13-405</pub-id>
<pub-id pub-id-type="pmid">22900683</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatraryamontri</surname><given-names>A.</given-names></name><name><surname>Breitkreutz</surname><given-names>B. J.</given-names></name><name><surname>Heinicke</surname><given-names>S.</given-names></name><name><surname>Boucher</surname><given-names>L.</given-names></name><name><surname>Winter</surname><given-names>A.</given-names></name><name><surname>Stark</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>The BioGRID interaction database: 2013 update</article-title>. <source>Nucleic Acids Res.</source>
<volume>41</volume>, <fpage>816</fpage>–<lpage>823</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks1158</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Dong</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>OAHG: an integrated resource for annotating human genes with multi-level ontologies</article-title>. <source>Sci. Rep.</source>
<volume>6</volume>, <fpage>34820</fpage>. <pub-id pub-id-type="doi">10.1038/srep34820</pub-id>
<pub-id pub-id-type="pmid">27703231</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Tian</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name><name><surname>Luo</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>LncRNA2Target v2.0: a comprehensive database for target genes of lncRNAs in human and mouse</article-title>. <source>Nucleic Acids Res.</source>
<volume>47</volume>, <fpage>D140</fpage>–<lpage>D144</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1051</pub-id>
<pub-id pub-id-type="pmid">30380072</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>I. F.</given-names></name><name><surname>Chen</surname><given-names>C.-Y.</given-names></name><name><surname>Su</surname><given-names>S.-C.</given-names></name><name><surname>Li</surname><given-names>C.-Y.</given-names></name><name><surname>Wu</surname><given-names>K.-J.</given-names></name><name><surname>Wang</surname><given-names>H.-W.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>DriverDBv2: a database for human cancer driver gene research</article-title>. <source>Nucleic Acids Res.</source>
<volume>44</volume>, <fpage>D975</fpage>–<lpage>D979</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv1314</pub-id>
<pub-id pub-id-type="pmid">26635391</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Z.</given-names></name><name><surname>Fei</surname><given-names>T.</given-names></name><name><surname>Verhaak</surname><given-names>R. G.</given-names></name><name><surname>Su</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer</article-title>. <source>Nat. Struct. Mol. Biol.</source>
<volume>20</volume>, <fpage>908</fpage>–<lpage>913</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb.2591</pub-id>
<pub-id pub-id-type="pmid">23728290</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elinav</surname><given-names>E.</given-names></name><name><surname>Nowarski</surname><given-names>R.</given-names></name><name><surname>Thaiss</surname><given-names>C. A.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Jin</surname><given-names>C.</given-names></name><name><surname>Flavell</surname><given-names>R. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms</article-title>. <source>Nat. Rev. Cancer</source>
<volume>13</volume>, <fpage>759</fpage>–<lpage>771</lpage>. <pub-id pub-id-type="doi">10.1038/nrc3611</pub-id>
<pub-id pub-id-type="pmid">24154716</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flicek</surname><given-names>P.</given-names></name><name><surname>Amode</surname><given-names>M. R.</given-names></name><name><surname>Barrell</surname><given-names>D.</given-names></name><name><surname>Beal</surname><given-names>K.</given-names></name><name><surname>Billis</surname><given-names>K.</given-names></name><name><surname>Brent</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Ensembl 2014</article-title>. <source>Nucleic Acids Res.</source>
<volume>42</volume>, <fpage>D749</fpage>–<lpage>D755</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1196</pub-id>
<pub-id pub-id-type="pmid">24316576</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto</surname><given-names>J.</given-names></name><name><surname>Aoki</surname><given-names>I.</given-names></name><name><surname>Toyoki</surname><given-names>H.</given-names></name><name><surname>Khatun</surname><given-names>S.</given-names></name><name><surname>Sato</surname><given-names>E.</given-names></name><name><surname>Sakaguchi</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers</article-title>. <source>Oncology</source>
<volume>66</volume>, <fpage>420</fpage>–<lpage>428</lpage>. <pub-id pub-id-type="doi">10.1159/000079491</pub-id>
<pub-id pub-id-type="pmid">15331930</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Futreal</surname><given-names>P. A.</given-names></name><name><surname>Coin</surname><given-names>L.</given-names></name><name><surname>Marshall</surname><given-names>M.</given-names></name><name><surname>Down</surname><given-names>T.</given-names></name><name><surname>Hubbard</surname><given-names>T.</given-names></name><name><surname>Wooster</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>A census of human cancer genes</article-title>. <source>Nat. Rev. Cancer</source>
<volume>4</volume>, <fpage>177</fpage>–<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1038/nrc1299</pub-id>
<pub-id pub-id-type="pmid">14993899</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grivennikov</surname><given-names>S. I.</given-names></name><name><surname>Greten</surname><given-names>F. R.</given-names></name><name><surname>Karin</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>Immunity, inflammation, and cancer</article-title>. <source>Cell</source>
<volume>140</volume>, <fpage>883</fpage>–<lpage>899</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2010.01.025</pub-id>
<pub-id pub-id-type="pmid">20303878</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D.</given-names></name><name><surname>Weinberg</surname><given-names>R. A.</given-names></name></person-group> (<year>2000</year>). <article-title>The hallmarks of cancer</article-title>. <source>Cell</source>
<volume>100</volume>, <fpage>57</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81683-9</pub-id>
<pub-id pub-id-type="pmid">10647931</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D.</given-names></name><name><surname>Weinberg</surname><given-names>R. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source>
<volume>144</volume>, <fpage>646</fpage>–<lpage>674</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>
<pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashemi</surname><given-names>J.</given-names></name><name><surname>Fotouhi</surname><given-names>O.</given-names></name><name><surname>Sulaiman</surname><given-names>L.</given-names></name><name><surname>Kjellman</surname><given-names>M.</given-names></name><name><surname>Hoog</surname><given-names>A.</given-names></name><name><surname>Zedenius</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Copy number alterations in small intestinal neuroendocrine tumors determined by array comparative genomic hybridization</article-title>. <source>BMC Cancer</source>
<volume>13</volume>, <fpage>505</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-13-505</pub-id>
<pub-id pub-id-type="pmid">24165089</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>T.</given-names></name><name><surname>Zang</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>L.</given-names></name></person-group> (<year>2018</year>). <article-title>Identification of Alzheimer's Disease-Related Genes Based on Data Integration Method</article-title>. <source>Front. Genet.</source>
<volume>9</volume>, <elocation-id>703</elocation-id>. <pub-id pub-id-type="doi">10.3389/fgene.2018.00703</pub-id>
<pub-id pub-id-type="pmid">30740125</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kan</surname><given-names>Z.</given-names></name><name><surname>Jaiswal</surname><given-names>B. S.</given-names></name><name><surname>Stinson</surname><given-names>J.</given-names></name><name><surname>Janakiraman</surname><given-names>V.</given-names></name><name><surname>Bhatt</surname><given-names>D.</given-names></name><name><surname>Stern</surname><given-names>H. M.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Diverse somatic mutation patterns and pathway alterations in human cancers</article-title>. <source>Nature</source>
<volume>466</volume>, <fpage>869</fpage>–<lpage>873</lpage>. <pub-id pub-id-type="doi">10.1038/nature09208</pub-id>
<pub-id pub-id-type="pmid">20668451</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandoth</surname><given-names>C.</given-names></name><name><surname>Mclellan</surname><given-names>M. D.</given-names></name><name><surname>Vandin</surname><given-names>F.</given-names></name><name><surname>Ye</surname><given-names>K.</given-names></name><name><surname>Niu</surname><given-names>B.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Mutational landscape and significance across 12 major cancer types</article-title>. <source>Nature</source>
<volume>502</volume>, <fpage>333</fpage>–<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1038/nature12634</pub-id>
<pub-id pub-id-type="pmid">24132290</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M.</given-names></name><name><surname>Furumichi</surname><given-names>M.</given-names></name><name><surname>Tanabe</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>Y.</given-names></name><name><surname>Morishima</surname><given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>KEGG: new perspectives on genomes, pathways, diseases and drugs</article-title>. <source>Nucleic Acids Res.</source>
<volume>45</volume>, <fpage>D353</fpage>–<lpage>D361</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw1092</pub-id>
<pub-id pub-id-type="pmid">27899662</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keshava Prasad</surname><given-names>T. S.</given-names></name><name><surname>Goel</surname><given-names>R.</given-names></name><name><surname>Kandasamy</surname><given-names>K.</given-names></name><name><surname>Keerthikumar</surname><given-names>S.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Mathivanan</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Human Protein Reference Database–2009 update</article-title>. <source>Nucleic Acids Res.</source>
<volume>37</volume>, <fpage>D767</fpage>–<lpage>D772</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn892</pub-id>
<pub-id pub-id-type="pmid">18988627</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laddha</surname><given-names>S. V.</given-names></name><name><surname>Ganesan</surname><given-names>S.</given-names></name><name><surname>Chan</surname><given-names>C. S.</given-names></name><name><surname>White</surname><given-names>E.</given-names></name></person-group> (<year>2014</year>). <article-title>Mutational landscape of the essential autophagy gene BECN1 in human cancers</article-title>. <source>Mol. Cancer Res.</source>
<volume>12</volume>, <fpage>485</fpage>–<lpage>490</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-13-0614</pub-id>
<pub-id pub-id-type="pmid">24478461</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladomery</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Aberrant alternative splicing is another hallmark of cancer</article-title>. <source>Int. J. Cell Biol.</source>
<volume>2013</volume>, <fpage>463786</fpage>. <pub-id pub-id-type="doi">10.1155/2013/463786</pub-id>
<pub-id pub-id-type="pmid">24101931</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H. K.</given-names></name><name><surname>Choung</surname><given-names>H. W.</given-names></name><name><surname>Yang</surname><given-names>Y. I.</given-names></name><name><surname>Yoon</surname><given-names>H. J.</given-names></name><name><surname>Park</surname><given-names>I. A.</given-names></name><name><surname>Park</surname><given-names>J. C.</given-names></name></person-group> (<year>2015</year>). <article-title>ODAM inhibits RhoA-dependent invasion in breast cancer</article-title>. <source>Cell Biochem. Funct.</source>
<volume>33</volume>, <fpage>451</fpage>–<lpage>461</lpage>. <pub-id pub-id-type="doi">10.1002/cbf.3132</pub-id>
<pub-id pub-id-type="pmid">26358398</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Lenferink</surname><given-names>A. E.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Collins</surname><given-names>C.</given-names></name><name><surname>Cui</surname><given-names>Q.</given-names></name><name><surname>Purisima</surname><given-names>E. O.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Identification of high-quality cancer prognostic markers and metastasis network modules</article-title>. <source>Nat. Commun.</source>
<volume>1</volume>, <fpage>34</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms1033</pub-id>
<pub-id pub-id-type="pmid">20975711</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A. X.</given-names></name><name><surname>Xin</surname><given-names>W. Q.</given-names></name><name><surname>Ma</surname><given-names>C. G.</given-names></name></person-group> (<year>2015</year>). <article-title>Fentanyl inhibits the invasion and migration of colorectal cancer cells <italic>via</italic> inhibiting the negative regulation of Ets-1 on BANCR</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>465</volume>, <fpage>594</fpage>–<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2015.08.068</pub-id>
<pub-id pub-id-type="pmid">26296467</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menyhart</surname><given-names>O.</given-names></name><name><surname>Harami-Papp</surname><given-names>H.</given-names></name><name><surname>Sukumar</surname><given-names>S.</given-names></name><name><surname>Schafer</surname><given-names>R.</given-names></name><name><surname>Magnani</surname><given-names>L.</given-names></name><name><surname>De Barrios</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Guidelines for the selection of functional assays to evaluate the hallmarks of cancer</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1866</volume>, <fpage>300</fpage>–<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbcan.2016.10.002</pub-id>
<pub-id pub-id-type="pmid">27742530</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montenegro</surname><given-names>M. F.</given-names></name><name><surname>Sanchez-Del-Campo</surname><given-names>L.</given-names></name><name><surname>Fernandez-Perez</surname><given-names>M. P.</given-names></name><name><surname>Saez-Ayala</surname><given-names>M.</given-names></name><name><surname>Cabezas-Herrera</surname><given-names>J.</given-names></name><name><surname>Rodriguez-Lopez</surname><given-names>J. N.</given-names></name></person-group> (<year>2015</year>). <article-title>Targeting the epigenetic machinery of cancer cells</article-title>. <source>Oncogene</source>
<volume>34</volume>, <fpage>135</fpage>–<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2013.605</pub-id>
<pub-id pub-id-type="pmid">24469033</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Q.</given-names></name><name><surname>Shai</surname><given-names>O.</given-names></name><name><surname>Lee</surname><given-names>L. J.</given-names></name><name><surname>Frey</surname><given-names>B. J.</given-names></name><name><surname>Blencowe</surname><given-names>B. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing</article-title>. <source>Nat. Genet.</source>
<volume>40</volume>, <fpage>1413</fpage>–<lpage>1415</lpage>. <pub-id pub-id-type="doi">10.1038/ng.259</pub-id>
<pub-id pub-id-type="pmid">18978789</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Guan</surname><given-names>J.</given-names></name><name><surname>Shang</surname><given-names>X.</given-names></name></person-group> (<year>2019</year>a). <article-title>Predicting Parkinson's Disease Genes Based on Node2vec and Autoencoder</article-title>. <source>Front. Genet.</source>
<volume>10</volume>, <elocation-id>226</elocation-id>. <pub-id pub-id-type="doi">10.3389/fgene.2019.00226</pub-id>
<pub-id pub-id-type="pmid">31001311</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Hui</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Hao</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2019</year>b). <article-title>A learning-based framework for miRNA-disease association identification using neural networks</article-title>. <source>Bioinformatics</source>
<volume>35</volume> (<issue>21</issue>), <fpage>4364</fpage>–<lpage>4371</lpage>. <pub-id pub-id-type="doi">10.1101/276048</pub-id>
<pub-id pub-id-type="pmid">30977780</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Shang</surname><given-names>X.</given-names></name></person-group> (<year>2019</year>c). <article-title>Combining gene ontology with deep neural networks to enhance the clustering of single cell RNA-Seq data</article-title>. <source>BMC Bioinf.</source>
<volume>20</volume>, <fpage>284</fpage>. <pub-id pub-id-type="doi">10.1186/s12859-019-2769-6</pub-id>
</mixed-citation>
    </ref>
    <ref id="B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>Y.</given-names></name><name><surname>Segura</surname><given-names>V.</given-names></name><name><surname>Marin-Bejar</surname><given-names>O.</given-names></name><name><surname>Athie</surname><given-names>A.</given-names></name><name><surname>Marchese</surname><given-names>F. P.</given-names></name><name><surname>Gonzalez</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature</article-title>. <source>Nat. Commun.</source>
<volume>5</volume>, <fpage>5812</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms6812</pub-id>
<pub-id pub-id-type="pmid">25524025</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sina</surname><given-names>A. A.</given-names></name><name><surname>Carrascosa</surname><given-names>L. G.</given-names></name><name><surname>Trau</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>DNA Methylation-Based Point-of-Care Cancer Detection: Challenges and Possibilities</article-title>. <source>Trends Mol. Med.</source>
<volume>25</volume> (<issue>11</issue>), <fpage>955</fpage>–<lpage>966</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2019.05.014</pub-id>
<pub-id pub-id-type="pmid">31253589</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stratton</surname><given-names>M. R.</given-names></name><name><surname>Campbell</surname><given-names>P. J.</given-names></name><name><surname>Futreal</surname><given-names>P. A.</given-names></name></person-group> (<year>2013</year>). <article-title>The Cancer Genome Atlas</article-title>. <source>Science</source>
<volume>320</volume>, <fpage>1958</fpage>.</mixed-citation>
    </ref>
    <ref id="B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>K.</given-names></name><name><surname>Duan</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Curcumin inhibits LPA-induced invasion by attenuating RhoA/ROCK/MMPs pathway in MCF7 breast cancer cells</article-title>. <source>Clin. Exp. Med.</source>
<volume>16</volume>, <fpage>37</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1007/s10238-015-0336-7</pub-id>
<pub-id pub-id-type="pmid">25596714</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D.</given-names></name><name><surname>Franceschini</surname><given-names>A.</given-names></name><name><surname>Kuhn</surname><given-names>M.</given-names></name><name><surname>Simonovic</surname><given-names>M.</given-names></name><name><surname>Roth</surname><given-names>A.</given-names></name><name><surname>Minguez</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored</article-title>. <source>Nucleic Acids Res.</source>
<volume>39</volume>, <fpage>D561</fpage>–<lpage>D568</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkq973</pub-id>
<pub-id pub-id-type="pmid">21045058</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>D. S.</given-names></name><name><surname>Iravani</surname><given-names>M.</given-names></name><name><surname>Mccluggage</surname><given-names>W. G.</given-names></name><name><surname>Lambros</surname><given-names>M. B.</given-names></name><name><surname>Milanezi</surname><given-names>F.</given-names></name><name><surname>Mackay</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas</article-title>. <source>Clin. Cancer Res.</source>
<volume>17</volume>, <fpage>1521</fpage>–<lpage>1534</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1688</pub-id>
<pub-id pub-id-type="pmid">21411445</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tate</surname><given-names>J. G.</given-names></name><name><surname>Bamford</surname><given-names>S.</given-names></name><name><surname>Jubb</surname><given-names>H. C.</given-names></name><name><surname>Sondka</surname><given-names>Z.</given-names></name><name><surname>Beare</surname><given-names>D. M.</given-names></name><name><surname>Bindal</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>COSMIC: the Catalogue Of Somatic Mutations In Cancer</article-title>. <source>Nucleic Acids Res.</source>
<volume>47</volume>, <fpage>D941</fpage>–<lpage>D947</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1015</pub-id>
<pub-id pub-id-type="pmid">30371878</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>E.</given-names></name><name><surname>Zaman</surname><given-names>N.</given-names></name><name><surname>Mcgee</surname><given-names>S.</given-names></name><name><surname>Milanese</surname><given-names>J. S.</given-names></name><name><surname>Masoudi-Nejad</surname><given-names>A.</given-names></name><name><surname>O'connor-Mccourt</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data</article-title>. <source>Semin. Cancer Biol.</source>
<volume>30</volume>, <fpage>4</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2014.04.002</pub-id>
<pub-id pub-id-type="pmid">24747696</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watabe</surname><given-names>T.</given-names></name><name><surname>Yoshida</surname><given-names>K.</given-names></name><name><surname>Shindoh</surname><given-names>M.</given-names></name><name><surname>Kaya</surname><given-names>M.</given-names></name><name><surname>Fujikawa</surname><given-names>K.</given-names></name><name><surname>Sato</surname><given-names>H.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor</article-title>. <source>Int. J. Cancer</source>
<volume>77</volume>, <fpage>128</fpage>–<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19980703)77:1&lt;128::AID-IJC20&gt;3.0.CO;2-9</pub-id>
<pub-id pub-id-type="pmid">9639404</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Integrating multiple genomic data to predict disease-causing nonsynonymous single nucleotide variants in exome sequencing studies</article-title>. <source>PloS Genet.</source>
<volume>10</volume>, <fpage>e1004237</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1004237</pub-id>
<pub-id pub-id-type="pmid">24651380</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Jia</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>3D genome of multiple myeloma reveals spatial genome disorganization associated with copy number variations</article-title>. <source>Nat. Commun.</source>
<volume>8</volume>, <fpage>1937</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-017-01793-w</pub-id>
<pub-id pub-id-type="pmid">29203764</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaman</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Jaramillo</surname><given-names>M. L.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Tibiche</surname><given-names>C.</given-names></name><name><surname>Banville</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets</article-title>. <source>Cell Rep.</source>
<volume>5</volume>, <fpage>216</fpage>–<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2013.08.028</pub-id>
<pub-id pub-id-type="pmid">24075989</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>H.</given-names></name><name><surname>Qiao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Formin-like2 regulates Rho/ROCK pathway to promote actin assembly and cell invasion of colorectal cancer</article-title>. <source>Cancer Sci.</source>
<volume>106</volume>, <fpage>1385</fpage>–<lpage>1393</lpage>. <pub-id pub-id-type="doi">10.1111/cas.12768</pub-id>
<pub-id pub-id-type="pmid">26258642</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Transcriptional regulation prediction of antiestrogen resistance in breast cancer based on RNA polymerase II binding data</article-title>. <source>BMC Bioinf.</source>
<volume>15 Suppl 2</volume>, <fpage>S10</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2105-15-S2-S10</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
